In view of KIS, it was considered to be a novel marker for personalized prediction of pancreatic cancer prognosis (Luo et al., 2022b) and was associated with a mechanism of non-genetic resistance to targeted therapy in melanoma (Smith et al., 2022). The gene discussed is UHMK1; the disease is melanoma.